drugset / Trial / NCT02191787

Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers

NCT02191787 ↗

Phase 1 Completed 10 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to determine the antioxidant potency of Seresis® in the serum of healthy volunteers and the optimal time for blood sampling

Timeline

Start
1998-03
Primary completion
1998-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Seresis® Unknown 2 unknown Oral

Indications

No indication recorded.